Cargando…

The Efficacy, the Treatment Response and the Aquaretic Effects of a Three-Year Tolvaptan Regimen in Polycystic Kidney Disease Patients

Tolvaptan, a selective vasopressin V2 receptor antagonist, is the first and only approved specific treatment for Autosomal-Dominant Polycystic Kidney Disease (ADPKD), and is used in current clinical practice. Real clinical data are missing. In this retrospective study, 41 ADPKD patients received tol...

Descripción completa

Detalles Bibliográficos
Autores principales: Gkika, Vasiliki, Louka, Michaela, Tsagkatakis, Mihail, Tsirpanlis, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514807/
https://www.ncbi.nlm.nih.gov/pubmed/37736928
http://dx.doi.org/10.3390/clinpract13050092
_version_ 1785108805674074112
author Gkika, Vasiliki
Louka, Michaela
Tsagkatakis, Mihail
Tsirpanlis, George
author_facet Gkika, Vasiliki
Louka, Michaela
Tsagkatakis, Mihail
Tsirpanlis, George
author_sort Gkika, Vasiliki
collection PubMed
description Tolvaptan, a selective vasopressin V2 receptor antagonist, is the first and only approved specific treatment for Autosomal-Dominant Polycystic Kidney Disease (ADPKD), and is used in current clinical practice. Real clinical data are missing. In this retrospective study, 41 ADPKD patients received tolvaptan for 3 years, from 2018 to 2021. Total kidney volume (TKV) was measured using Magnetic Resonance Imaging, at initiation and at the end of the treatment period. A complete biochemistry/hematology profile and a 24 h urine volume collection were performed monthly for the first 18 months and every 3 months thereafter. At the end of the treatment period, the median (IQR) estimated Glomerular Filtration Rate (e-GFR) was 5.3 (−1.3, 8.7) mL/min higher than the expected e-GFR decline without treatment, while the prediction for End Stage Chronic Kidney Disease (ESKD) had been prolonged by 1 (0, 2) year. Total Kidney Volume did not change significantly (2250 (1357) mL at 3 years of treatment vs. 2180 (1091) mL expected without treatment, p = 0.48). Younger patients with a relatively preserved e-GFR, lower hypertension burden, better familiar renal prognosis and more severe imaging data showed better outcomes. The aquaretic adverse effects of tolvaptan did not affect renal function and electrolyte balance in 51 patients, in a follow-up period of 18 months. Consequently, tolvaptan seems to be effective in preventing progression of ADPKD when administered in a timely manner in patients with better familiar renal history, shorter hypertension duration and worse imaging profile. Increased diuresis does not affect treatment efficacy.
format Online
Article
Text
id pubmed-10514807
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105148072023-09-23 The Efficacy, the Treatment Response and the Aquaretic Effects of a Three-Year Tolvaptan Regimen in Polycystic Kidney Disease Patients Gkika, Vasiliki Louka, Michaela Tsagkatakis, Mihail Tsirpanlis, George Clin Pract Article Tolvaptan, a selective vasopressin V2 receptor antagonist, is the first and only approved specific treatment for Autosomal-Dominant Polycystic Kidney Disease (ADPKD), and is used in current clinical practice. Real clinical data are missing. In this retrospective study, 41 ADPKD patients received tolvaptan for 3 years, from 2018 to 2021. Total kidney volume (TKV) was measured using Magnetic Resonance Imaging, at initiation and at the end of the treatment period. A complete biochemistry/hematology profile and a 24 h urine volume collection were performed monthly for the first 18 months and every 3 months thereafter. At the end of the treatment period, the median (IQR) estimated Glomerular Filtration Rate (e-GFR) was 5.3 (−1.3, 8.7) mL/min higher than the expected e-GFR decline without treatment, while the prediction for End Stage Chronic Kidney Disease (ESKD) had been prolonged by 1 (0, 2) year. Total Kidney Volume did not change significantly (2250 (1357) mL at 3 years of treatment vs. 2180 (1091) mL expected without treatment, p = 0.48). Younger patients with a relatively preserved e-GFR, lower hypertension burden, better familiar renal prognosis and more severe imaging data showed better outcomes. The aquaretic adverse effects of tolvaptan did not affect renal function and electrolyte balance in 51 patients, in a follow-up period of 18 months. Consequently, tolvaptan seems to be effective in preventing progression of ADPKD when administered in a timely manner in patients with better familiar renal history, shorter hypertension duration and worse imaging profile. Increased diuresis does not affect treatment efficacy. MDPI 2023-08-24 /pmc/articles/PMC10514807/ /pubmed/37736928 http://dx.doi.org/10.3390/clinpract13050092 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gkika, Vasiliki
Louka, Michaela
Tsagkatakis, Mihail
Tsirpanlis, George
The Efficacy, the Treatment Response and the Aquaretic Effects of a Three-Year Tolvaptan Regimen in Polycystic Kidney Disease Patients
title The Efficacy, the Treatment Response and the Aquaretic Effects of a Three-Year Tolvaptan Regimen in Polycystic Kidney Disease Patients
title_full The Efficacy, the Treatment Response and the Aquaretic Effects of a Three-Year Tolvaptan Regimen in Polycystic Kidney Disease Patients
title_fullStr The Efficacy, the Treatment Response and the Aquaretic Effects of a Three-Year Tolvaptan Regimen in Polycystic Kidney Disease Patients
title_full_unstemmed The Efficacy, the Treatment Response and the Aquaretic Effects of a Three-Year Tolvaptan Regimen in Polycystic Kidney Disease Patients
title_short The Efficacy, the Treatment Response and the Aquaretic Effects of a Three-Year Tolvaptan Regimen in Polycystic Kidney Disease Patients
title_sort efficacy, the treatment response and the aquaretic effects of a three-year tolvaptan regimen in polycystic kidney disease patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514807/
https://www.ncbi.nlm.nih.gov/pubmed/37736928
http://dx.doi.org/10.3390/clinpract13050092
work_keys_str_mv AT gkikavasiliki theefficacythetreatmentresponseandtheaquareticeffectsofathreeyeartolvaptanregimeninpolycystickidneydiseasepatients
AT loukamichaela theefficacythetreatmentresponseandtheaquareticeffectsofathreeyeartolvaptanregimeninpolycystickidneydiseasepatients
AT tsagkatakismihail theefficacythetreatmentresponseandtheaquareticeffectsofathreeyeartolvaptanregimeninpolycystickidneydiseasepatients
AT tsirpanlisgeorge theefficacythetreatmentresponseandtheaquareticeffectsofathreeyeartolvaptanregimeninpolycystickidneydiseasepatients
AT gkikavasiliki efficacythetreatmentresponseandtheaquareticeffectsofathreeyeartolvaptanregimeninpolycystickidneydiseasepatients
AT loukamichaela efficacythetreatmentresponseandtheaquareticeffectsofathreeyeartolvaptanregimeninpolycystickidneydiseasepatients
AT tsagkatakismihail efficacythetreatmentresponseandtheaquareticeffectsofathreeyeartolvaptanregimeninpolycystickidneydiseasepatients
AT tsirpanlisgeorge efficacythetreatmentresponseandtheaquareticeffectsofathreeyeartolvaptanregimeninpolycystickidneydiseasepatients